e-learning
resources
2021
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Indirect comparison of efficacy of dupilumab
versus
mepolizumab and omalizumab for severe type 2 asthma
Katrine Prætorius, Daniel P. Henriksen, Johannes M. Schmid, Pernille Printzlau, Lars Pedersen, Hanne Madsen, Ehm A. Andersson, Louise Klokker Madsen, Bo L. Chawes
Source:
ERJ Open Res, 7 (3) 00306-2021; 10.1183/23120541.00306-2021
Journal Issue:
July
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Katrine Prætorius, Daniel P. Henriksen, Johannes M. Schmid, Pernille Printzlau, Lars Pedersen, Hanne Madsen, Ehm A. Andersson, Louise Klokker Madsen, Bo L. Chawes. Indirect comparison of efficacy of dupilumab
versus
mepolizumab and omalizumab for severe type 2 asthma. ERJ Open Res, 7 (3) 00306-2021; 10.1183/23120541.00306-2021
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Respiratory sequelae of preterm birth across the life span
Time to breathe: Challenges in the successful management of asthma during conception, pregnancy and delivery
Related content which might interest you:
Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial
Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Year: 2020
Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
Source: Virtual Congress 2020 – How do different treatment strategies translate into costs
Year: 2020
Evaluating the efficacy of omalizumab in severe persistent asthma patients
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Comparison of the efficacy of cicleosonide with budesonide in mild to moderate asthma patients after step-down therapy
Source: Annual Congress 2011 - Asthma management and response
Year: 2011
The efficacy of omalizumab in severe in asthma after treatment withdrawal
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Comparison of efficacy and safety of Obucort Swinghaler with Pulmicot Turbuhaler in mild to moderate severe asthma patients
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010
Cost analysis for patients with severe asthma receiving omalizumab treatment
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019
Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Efficacy and safety of long-term therapy with Salamol combined with Beclason
versus
Salamol only in patients with mild persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 42s
Year: 2002
Efficacy of as-needed budesonide/formoterol in mild asthma: pooled analysis of SYGMA 1 and 2
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020
Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 440s
Year: 2006
Anti-inflammatory effect and clinical efficacy of concomitant treatments to steroid inhaler in bronchial asthma: montelukast
versus
salmeterol
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006
Long-term safety and tolerability of omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
Efficacy of long-term formoterol therapy
vs
as-needed salbutamol use in patients with moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 426s
Year: 2001
Comparative effectiveness of add-on omalizumab for the treatment of severe persistent asthma between current and former smokers vs. non-smokers
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010
Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
Source: International Congress 2017 – Asthma management
Year: 2017
Cost-effectiveness of fluticasone/salmeterol inhaler in treatment of moderate and severe bronchial asthma
Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma
Year: 2008
Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide - a cost-effectiveness analysis
Source: Eur Respir J 2001; 18: Suppl. 33, 517s
Year: 2001
Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010
Which patients should be treated with anti-IgE?
Source: Eur Respir Rev 2007; 16: 85-87
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept